摘要
目的探讨ZBTB7A在肝癌组织中的表达,并分析其与肝癌耐药性产生的关系。方法运用UALCAN法检测371例TCGA肝癌标本中ZBTB7A的表达,应用Western blot法检测肝癌组织与癌旁组织中ZBTB7A的蛋白表达水平。荧光定量PCR和Western blot分别检测阿霉素耐药细胞中ZBTB7A的表达。采用TIMER数据库以及荧光定量PCR分析ZBTB7A的表达与耐药相关基因的关系。结果ZBTB7A基因在肝癌组织中高表达,且与肿瘤分期存在密切关系;在阿霉素耐药的Bel7402细胞中,ZBTB7A的表达上调,并且ZBTB7A的表达与BCL-2相关抗凋亡基因及ABCC1的表达呈正相关;干扰ZBTB7A表达能够下调BCL-2相关抗凋亡基因及ABCC1的表达。结论ZBTB7A在耐药细胞中的表达上调,干扰ZBTB7A的表达能够抑制BCL-2相关抗凋亡基因及ABCC1的表达,肝癌中ZBTB7A的表达与耐药性的产生存在密切联系。
Purpose To evaluate the expression of ZBTB7A and the correlation with drug resistance in hepatocellular carcinoma(HCC).Methods The expression of ZBTB7A in 371 cases hepatocellular carcinoma of TCGA data was detected by UALCAN method,and the protein levels of ZBTB7A in HCC tissue and paracancerous tissues was detected by Western blot methods.The mRNA and protein expression of ZBTB7A in doxorubicin(DOX)resistant cells was detected by fluorescent quantitative real-time poly-chain-reaction(qRT-PCR)and Western blot.The correlation between ZBTB7A expresision and drug resistant related genes was analyzed by tumor IMmune estimation resource(TIMER)database and qRT-PCR.Result ZBTB7A was overexpressed in hepatocellular carcinoma and closely correlated with tumor stage.ZBTB7A expression was significantly elevated in DOX-resistant Bel7402 cells.The expression of ZBTB7A positively correlated with BCL-2 related anti-apoptotic genes and ABCC1.Knockdown of ZBTB7A could down-regulate the expression of BCL-2-related anti-apoptotic genes and ABCC1.Conclusion ZBTB7A expression is up-regulated in drug-resistant cells.Silencing ZBTB7A can inhibit the expression of BCL-2-related anti-apoptotic genes and ABCC1.The expression of ZBTB7A is closely correlated with drug resistant in HCC.
作者
张健
赵素平
吕飒美
吴友伟
王宗艳
王国荣
史丽萍
ZHANG Jian;ZHAO Su-ping;L Sa-mei;WU You-wei;WANG Zong-yan;WANG Guo-rong;SHI Li-ping(Department of Gastroenterology,Shanxi Provincial People’s Hospital,Xi’an 710068,China;Department of General Surgery,Shanxi Provincial People’s Hospital,Xi’an 710068,China)
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2019年第10期1156-1161,共6页
Chinese Journal of Clinical and Experimental Pathology
基金
西安市科技计划[2017113SF/YX007(14)]
